Range Financial Group LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)

Range Financial Group LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 72.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,547 shares of the biopharmaceutical company’s stock after buying an additional 5,672 shares during the quarter. Range Financial Group LLC’s holdings in Pfizer were worth $376,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Lloyd Advisory Services LLC. increased its position in shares of Pfizer by 132.2% in the first quarter. Lloyd Advisory Services LLC. now owns 22,685 shares of the biopharmaceutical company’s stock valued at $629,000 after buying an additional 12,915 shares in the last quarter. CHICAGO TRUST Co NA increased its position in shares of Pfizer by 21.5% during the first quarter. CHICAGO TRUST Co NA now owns 41,830 shares of the biopharmaceutical company’s stock worth $1,161,000 after purchasing an additional 7,400 shares in the last quarter. Northwest Investment Counselors LLC purchased a new stake in shares of Pfizer during the first quarter worth approximately $89,000. Game Plan Financial Advisors LLC increased its position in shares of Pfizer by 1,671.4% during the first quarter. Game Plan Financial Advisors LLC now owns 3,100 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 2,925 shares in the last quarter. Finally, Abacus Planning Group Inc. increased its position in shares of Pfizer by 3.8% during the first quarter. Abacus Planning Group Inc. now owns 26,559 shares of the biopharmaceutical company’s stock worth $737,000 after purchasing an additional 980 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 2.2 %

NYSE:PFE opened at $28.36 on Tuesday. The stock’s 50 day moving average price is $27.72 and its 200 day moving average price is $27.70. The company has a market capitalization of $160.68 billion, a PE ratio of -472.50, a P/E/G ratio of 1.09 and a beta of 0.70. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.23 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.37 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were given a dividend of $0.42 per share. The ex-dividend date was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 5.92%. Pfizer’s payout ratio is -2,799.53%.

Wall Street Analyst Weigh In

Several analysts recently commented on PFE shares. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, June 17th. Finally, Morgan Stanley boosted their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.